{"id":"https://openalex.org/A5093448409","orcid":"https://orcid.org/0009-0006-5598-6374","observed_orcids":["https://orcid.org/0009-0006-5598-6374"],"display_name":"J. Daniel McGeeney","raw_author_names":["J. Daniel McGeeney","J. McGeeney","J.D. McGeeney"],"full_name":"J. Daniel McGeeney","works_count":5,"cited_by_count":13,"summary_stats":{"2yr_mean_citedness":2.0,"h_index":2,"i10_index":0},"ids":{"openalex":"https://openalex.org/A5093448409","orcid":"https://orcid.org/0009-0006-5598-6374","observed_orcids":["https://orcid.org/0009-0006-5598-6374"]},"affiliations":[{"institution":{"id":"https://openalex.org/I4210139872","ror":"https://ror.org/03vff5r77","display_name":"Eastern Research Group (United States)","country_code":"US","type":"company","lineage":["https://openalex.org/I4210139872"]},"years":[2025,2024,2023]}],"last_known_institutions":[{"id":"https://openalex.org/I4210139872","ror":"https://ror.org/03vff5r77","display_name":"Eastern Research Group (United States)","country_code":"US","type":"company","lineage":["https://openalex.org/I4210139872"]}],"topics":[{"id":"https://openalex.org/T11792","display_name":"Pharmaceutical Economics and Policy","count":3,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","count":2,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T12255","display_name":"Biosimilars and Bioanalytical Methods","count":2,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10118","display_name":"SARS-CoV-2 and COVID-19 Research","count":1,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10252","display_name":"Microbial Natural Products and Biosynthesis","count":1,"subfield":{"id":"https://openalex.org/subfields/2402","display_name":"Applied Microbiology and Biotechnology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"topic_share":[{"id":"https://openalex.org/T12255","display_name":"Biosimilars and Bioanalytical Methods","value":2.34e-05,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11792","display_name":"Pharmaceutical Economics and Policy","value":1.21e-05,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","value":5.3e-06,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T10410","display_name":"COVID-19 epidemiological studies","value":5e-06,"subfield":{"id":"https://openalex.org/subfields/2611","display_name":"Modeling and Simulation"},"field":{"id":"https://openalex.org/fields/26","display_name":"Mathematics"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},{"id":"https://openalex.org/T10856","display_name":"Intellectual Property and Patents","value":4.9e-06,"subfield":{"id":"https://openalex.org/subfields/1405","display_name":"Management of Technology and Innovation"},"field":{"id":"https://openalex.org/fields/14","display_name":"Business, Management and Accounting"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}}],"x_concepts":[{"id":"59491497","wikidata":"https://www.wikidata.org/wiki/Q864715","display_name":"Biosimilar","score":0.9926270246505737},{"id":"144133560","wikidata":"https://www.wikidata.org/wiki/Q4830453","display_name":"Business","score":0.5625015497207642},{"id":"71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","score":0.4803560972213745},{"id":"126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","score":0.15301692485809326},{"id":"105795698","wikidata":"https://www.wikidata.org/wiki/Q12483","display_name":"Statistics","score":0.08478912711143494}],"counts_by_year":[{"year":2023,"works_count":1,"oa_works_count":0,"cited_by_count":0},{"year":2024,"works_count":1,"oa_works_count":1,"cited_by_count":3},{"year":2025,"works_count":3,"oa_works_count":2,"cited_by_count":3},{"year":2026,"works_count":0,"oa_works_count":0,"cited_by_count":7}],"display_name_alternatives":["J. Daniel McGeeney","J. McGeeney","J.D. McGeeney"],"block_key":"j mcgeeney","works_api_url":"https://api.openalex.org/works?filter=author.id:A5093448409","awards_count":0,"updated_date":"2026-11-07T12:08:38","created_date":"2023-12-09T00:00:00"}